Ovarian Carcinoma-associated Antigen Antibody (OV632): sc-52353

Ovarian Carcinoma-associated Antigen Antibody (OV632) is a mouse monoclonal IgG2b antibody that detects Ovarian Carcinoma-associated Antigen of human origin by immunofluorescence (IF) and flow cytometry (FCM). Anti-Ovarian Carcinoma-associated Antigen antibody (OV632) is available as the non-conjugated form. Ovarian Carcinoma-associated Antigen plays a crucial role in the diagnosis and treatment of ovarian cancer, a disease characterized by malignant growth of cells in the ovaries. Ovarian Carcinoma-associated Antigen is particularly significant because of its association with human folate receptor-α (FR-α), a protein selectively overexpressed in ovarian carcinoma. FR-α overexpression not only aids in ovarian cancer identification but also presents a potential therapeutic target, as FR-α is involved in folate uptake, essential for DNA synthesis and repair. FR-α presence in ovarian cancer cells can lead to increased tumor growth and resistance to certain treatments, making FR-α a critical focus for ongoing research and clinical applications. Anti-Ovarian Carcinoma-associated Antigen antibody (OV632) specifically targeting these antigens serves as an invaluable tool in both early detection and development of targeted therapies for ovarian cancer, ultimately contributing to improved patient outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ovarian Carcinoma-associated Antigen Antibody (OV632) References:

1. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice.  |  Neglia, F., et al. 1999. Cancer Gene Ther. 6: 349-57. PMID: 10419053
2. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.  |  Lamers, CH., et al. 1992. Int J Cancer. 51: 973-9. PMID: 1386349
3. Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice.  |  Chang, XH., et al. 2006. Chin Med J (Engl). 119: 131-9. PMID: 16454995
4. An evaluation of ovarian carcinoma-associated antigen defined by murine monoclonal antibody CF511 in sera from patients with ovarian carcinoma.  |  Ohkawa, K., et al. 1991. Br J Cancer. 64: 259-62. PMID: 1892754
5. A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers.  |  Horowitz, AT., et al. 1985. Oncology. 42: 332-7. PMID: 2412195
6. Serum levels and biochemical characteristics of human ovarian carcinoma-associated antigen defined by murine monoclonal antibody, CF511.  |  Ohkawa, K., et al. 1989. Br J Cancer. 60: 953-60. PMID: 2605105
7. Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma.  |  Mittal, KR., et al. 1995. Histochem J. 27: 119-22. PMID: 7775195
8. Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.  |  van Hof, AC., et al. 1996. Cancer Res. 56: 5179-85. PMID: 8912854
9. Anti-TAG-72 antibody B72.3--immunological and clinical effects in ovarian carcinoma.  |  Schmolling, J., et al. 1997. Hybridoma. 16: 53-8. PMID: 9085129